Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield OK Pharmacy Coverage & PA P…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - OklahomaPolicy N/A

    2025 Drug List (Pharmacy Benefit) — Formulary, Utilization Management, and Specialty Drug Guidance

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Oklahoma policy alerts

    Know when Blue Cross Blue Shield - Oklahoma releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Provides Blue Cross Blue Shield of Oklahoma's 2025 pharmacy drug list, member cost-tiering, coverage considerations (including prior authorization, step therapy, quantity limits), specialty drug guidance, and processes for exceptions and appeals; intended for BCBSOK members, prescribing clinicians, pharmacists, and network providers.

    Policy Summary
    PayerBlue Cross Blue Shield - Oklahoma
    Policy2025 Drug List (Pharmacy Benefit) — Formulary & Utilization Controls
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization and submit supporting documentation when a drug is listed with 'PA' or 'PA, QL' to avoid claim denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~120+distinct drug line-items in this extract
    multipleentries with PA or QL
    MyPrime.comwebsites for current list
    30/90day supply guidance
    OKapplicability

    Coverage and General Pharmacy Rules

    General pharmacy coverage

    Covered when ALL of the following are met:

    General coverage conditions: Drug is listed on the BCBSOK Drug List (the member’s plan drug list) and the member’s specific benefit includes coverage for the drug category;

    From statement that all available covered drugs are shown and drugs not shown are not covered.

    Regulatory and guideline conformity: The drug is FDA‑approved for the requested indication or otherwise covered per the member’s plan (non‑FDA‑approved drugs are excluded); coverage follows FDA labeling and recognized evidence‑based or clinical practice guidelines where specified;

    Reflects non‑FDA‑approved drugs exclusion and limitation to FDA‑approved labeling/guidelines.

    Utilization management requirements: Any applicable prior authorization (PA), step therapy (ST), dispensing/quantity limits (QL), or specialty pharmacy (SP) requirements listed for the product are satisfied prior to benefit payment; if PA or ST commonly applies it will be noted with 'PA' or 'ST' in the Special Requirements column; QL indicates dispensing limits per period (e.g., 30 tablets/30 days);
    Policy Summary
    PayerBlue Cross Blue Shield - Oklahoma
    Policy2025 Drug List (Pharmacy Benefit) — Formulary & Utilization Controls
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization and submit supporting documentation when a drug is listed with 'PA' or 'PA, QL' to avoid claim denial.
    SourceLink
    On This Page
    Coverage and General Pharmacy RulesDrug List and Coding ReferencesPrior Authorization, Step Therapy, Documentation, and Denial RisksStep Edits and SequencesQuantity Limits (QL) by ProductSite of Care and Specialty Pharmacy RoutingAbbreviations and Key DefinitionsBackground and Scope

    Derived from PA/ST/QL descriptions and guidance to check Special Requirements column.

    Site‑of‑care and dispensing channel: If the product is designated specialty (SP) or requires administration by a health care professional, coverage and routing must follow the payer’s specialty or medical‑benefit processes (e.g., specialty pharmacy, infusion/office billing) as indicated;

    Based on statements that SP products are managed through specialty pharmacy and that medications administered by providers may be medical‑benefit rather than pharmacy.

    Plan‑level exceptions and member responsibility: If a prescribed quantity exceeds a listed QL or the drug is not on the Drug List, the prescriber or member may request a Drug List exception or supply documentation for PA; decisions and timelines follow plan procedures (exception decisions: standard 15 calendar days; expedited 72 hours); members may be responsible for cost beyond allowed quantities if dispensing limits are exceeded or PA is not obtained;

    From exception process timelines and consequences for exceeding QL or lacking PA.

    Drugs that are not shown on the Drug List are not covered. The Drug List represents the medications the plan will consider for payment under the pharmacy benefit and coverage is subject to the member's specific plan rules and any utilization controls shown on the list (for example, PA, QL, or SP). Examples of exclusions called out in the plan materials include drugs indicated for cosmetic purposes (e.g., hair-growth agents), products with available over‑the‑counter equivalents, repackaged medications, and medications that are not FDA‑approved for the intended use or for self‑administration. Members and prescribers should check benefit-specific materials or contact the number on the member ID card for coverage determinations.

    The policy explicitly states that non‑FDA‑approved drugs are not covered. Prior to coverage, drugs must be FDA‑approved for the indicated use unless an exception is granted per the member's benefit; prescribers should verify coverage and, when appropriate, submit an exception request following the payer's process.

    Drug List and Coding References

    Drug list (no CPT/ICD/NDC codes in these chunks)mixed
    noneThis extract contains drug names, tiers and requirement flags but no procedure or diagnosis codes.
    inv-05: Example Quantity Limit — 60 tablets/30 days
    Example QL60 tablets/30 days
    ContextIllustrative example quantity limit from the drug list
    Where notedShown as QL in the Requirements/Limits column
    inv-06: Example Quantity Limit — 30 tablets/30 days
    Example QL30 tablets/30 days
    ContextIllustrative example quantity limit from the drug list
    Where notedShown as QL in the Requirements/Limits column
    inv-07: Enalapril oral solution quantity limit (1200 mls/30 days)
    Enalapril oral solution (Epaned)QL 1200 mls/30 days
    RequirementsListed with PA and QL in the drug list entry
    Unitmilliliters per 30 days
    inv-08: FUROSCIX quantity limit (8 kits/180 days)
    FUROSCIX (furosemide subcutaneous cartridge kit)QL 8 kits/180 days
    RequirementsEntry lists PA and QL for the kit
    Interval180-day window
    inv-09: REPATHA syringe/pen/cartridge quantity limits
    REPATHA - prefilled syringeQL 6 syringes/28 days
    REPATHA - cartridge (Pushtronex)QL 2 cartridges/30 days
    REPATHA - SureClick/penQL 6 pens/28 days
    inv-10: ADEMPAS quantity limit (90 tablets/30 days)
    ADEMPAS (riociguat)QL 90 tablets/30 days
    RequirementsListed with PA and QL in the cardiovascular agents section
    Unittablets per 30 days
    inv-11: UPTRAVI quantity limit (60 tablets/30 days)
    UPTRAVI (selexipag)QL 60 tablets/30 days
    RequirementsEntry lists PA and QL and SP designation
    Unittablets per 30 days

    Prior Authorization, Step Therapy, Documentation, and Denial Risks

    Prior Authorization

    Obtain Prior Authorization when 'PA' is listed

    Prescribers must obtain prior authorization (PA) when a drug’s Requirements/Limits column shows “PA”; PA will be noted next to medications for which approval is commonly required and must be approved before the medication is covered under the plan.

    Prior Authorization

    PA required for select inhaled/specialty agents

    Prior authorization is required for selected inhaled antimicrobials and certain antifungal agents — examples include ARIKAYCE and KITABIS PAK; check the line-item Requirements/Limits for the PA designation before dispensing.

    • ARIKAYCE — Requirements/Limits = PA, QL (235.2 mls/28 days), SP
    • KITABIS PAK — Requirements/Limits = PA, QL (56 containers/56 days), SP
    Prior Authorization

    PA required for select antivirals / HCV regimens

    Prior authorization is required for specified high‑cost antiviral and hepatitis C regimens; these products are listed with “PA” (and often QL and SP) and require prescriber PA prior to coverage.

    • EPCLUSA, HARVONI, MAVYRET, SOVALDI — listed with Requirements/Limits = PA, QL and SP
    Prior Authorization

    PA required for many specialty/oncology agents

    Many oncology and specialty drugs in this section show “PA” in Requirements/Limits; prescribers must secure prior authorization before these specialty/oncology agents will be covered.

    • Examples: abiraterone (Zytiga) Requirements/Limits = PA, QL, SP; many antineoplastics list PA and SP
    Prior Authorization

    PA plus quantity limits required for specialty agents

    Prescribers must obtain prior authorization and comply with quantity limits (QL) for many oncology and specialty drugs; individual entries list the exact QL and SP designations that must be honored.

    • Examples show PA plus QL (e.g., acalabrutinib PA, QL 60 tablets/30 days, SP)
    Prior Authorization

    Obtain PA before coverage is allowed

    Providers must request prior authorization for drugs where the Requirements/Limits column indicates “PA”; coverage will not be allowed until the PA is approved per the plan’s process.

    Prior Authorization

    PA and QL required for select antidiabetic injectables

    Certain GLP‑1 and related antidiabetic injectables require prior authorization and have specified quantity limits; submit PA and ensure requested quantities match the QL for the listed strength.

    • MOUNJARO — Requirements/Limits = PA, QL (4 pens/180 days or 4 pens/28 days depending on strength)
    • OZEMPIC — Requirements/Limits = PA, QL (1 pen/28 days or 3 mL/28 days depending on presentation)
    • RYBELSUS, TRULICITY — listed with PA and QL
    Prior Authorization

    PA required for listed specialty products

    Prescribers must obtain prior authorization for the listed specialty products; check each product line (e.g., MYALEPT, OMNITROPE) for the PA notation before dispensing.

    • MYALEPT — Requirements/Limits = PA, SP
    • OMNITROPE — Requirements/Limits = PA, SP
    Prior Authorization

    PA required for specialty pulmonary/cardiac agents

    Prior authorization is required for multiple specialty agents including PAH and cardiology therapies; confirm PA (and any QL/SP) on products such as ADEMPAS, REPATHA and CAMZYOS before coverage.

    • ADEMPAS — Requirements/Limits = PA, QL (90 tablets/30 days), SP
    • REPATHA — Requirements/Limits = PA, QL (device-specific limits), SP
    Prior Authorization

    PA required for many specialty / high‑cost drugs

    Many specialty and high‑cost drugs in this excerpt are listed with “PA”; prescribers must submit PA requests and follow specialty routing (SP) when indicated to avoid coverage delays or denials.

    • Specialty products frequently show Requirements/Limits = PA and SP (see individual entries for QL)
    Prior Authorization

    PA required for specified specialty agents

    Prior authorization is required for several specified products listed with PA in the Requirements/Limits field (examples include KALYDECO, TRIKAFTA, OFEV); obtain PA prior to dispensing to prevent denial.

    • KALYDECO — Requirements/Limits = PA, QL (60 tablets/30 days), SP
    • TRIKAFTA — Requirements/Limits = PA, QL (56 packets/28 days or 90 tablets/30 days), SP
    Prior Authorization

    PA required for select listed drugs

    Prescribers must obtain prior authorization for products explicitly designated “PA” in the Requirements/Limits field (examples in Part 15 include IMCIVREE, Hetlioz LQ, LOMAIRA); check each line for PA before coverage.

    • IMCIVREE — Requirements/Limits = PA, QL (10 vials/30 days), SP
    • WEGOVY — Requirements/Limits = PA, QL (8 pens/180 days or 4 pens/28 days), SP
    Prior Authorization

    PA required for other listed drugs

    Prior authorization is required for additional listed drugs such as fingolimod and other Part 15 entries; coverage may be denied if PA is not obtained.

    • GILENYA (fingolimod) — fingolimod 0.25 mg requires PA and QL in some presentations
    Denial Risk

    Risk of denial if PA not obtained

    Coverage may be denied if prior authorization is not obtained for drugs labeled “PA” in the Requirements/Limits column; providers must secure PA per the plan’s process to avoid claim denials.

    Step Therapy

    Follow Step Therapy when 'ST' is shown

    Some benefit plans use step therapy; when a drug is marked “ST” in Requirements/Limits the member may need to try a preferred alternative first before the requested drug is covered.

    • If “ST” appears next to a drug, follow the plan’s step therapy sequence before requesting PA (if applicable).
    Note

    Follow payer operational procedures for PA and exceptions

    Follow nearby operational instructions and payer contact procedures for PA submissions, exceptions, and utilization management as noted in the drug list and exception process.

    • Call the number on the member’s ID card for exception requests or questions.
    • Refer to the drug’s Requirements/Limits line for exact PA/ST/QL flags.
    Note

    No step therapy sequences shown here — check Requirements/Limits

    Step therapy specifics are not shown in this excerpt; where step therapy applies it will be indicated in the Requirements/Limits field next to the drug (look for “ST”).

    Note

    Observe access (AC) / administrative codes where shown

    Some entries include access (AC) or administrative designations; when present these codes and any accompanying “ST”/“PA” notes must be followed as indicated in the Requirements/Limits column.

    • Contraceptive examples show AC and QL — follow the access/administrative instructions listed.
    Note

    Step therapy details not present — verify per line-item

    This extract does not include explicit step therapy sequences for most drugs; verify the Requirements/Limits column for any “ST” instructions when prescribing.

    Step Therapy

    Step therapy / step edits apply to many specialty agents

    Many specialty agents are flagged with step edits (SP/ST) in Requirements/Limits; prescribers must follow the step therapy or specialty access rules listed for each product.

    • SP flags often accompany PA and QL for specialty drugs — follow specialty routing and step edits as indicated.
    Step Therapy

    Adhere to step therapy edits for 'ST'‑flagged products

    Some specific products are marked with “ST” (step therapy) in Requirements/Limits (examples include risperidone ODT, Secuado, Versacloz); prescribers must meet the step requirements for these entries.

    • Risperidone ODT, Secuado patch, Versacloz suspension — listed with ST in Requirements/Limits
    Step Therapy

    Comply with step therapy for entries marked 'ST'

    When a drug’s Requirements/Limits field lists “ST,” prescribers must follow the step therapy rules indicated for coverage of that product (examples include Gralise entries).

    • Gralise (gabapentin once-daily) entries include ST and QL — follow step requirements.
    Documentation Required

    Submit drug list exceptions by phone; note decision timelines

    For Drug List exceptions, prescribers or members must call the number on the member’s ID card; BCBSOK will notify the decision within 15 calendar days (or 72 hours for expedited requests).

    • Expedited requests: decision within 72 calendar hours.
    • Standard requests: decision within 15 calendar days.
    Documentation Required

    Include supporting documentation with PA/QL requests

    When requesting prior authorization or to meet quantity limits, submit supporting clinical documentation such as diagnosis, prior therapy history, and justification for the requested quantity or dispensing interval.

    • Include diagnosis and prior treatment tried when PA or SP is indicated.
    • Provide quantity/dispensing interval justification when QL is listed.
    Documentation Required

    Supply PA/SP supporting documentation (diagnosis, prior therapy, quantity)

    When a product is listed with “PA” or “SP,” prescribers must supply documentation consistent with PA/specialty policies (diagnosis, prior therapy, and quantity rationale) to support coverage.

    Documentation Required

    PA entries require prior authorization documentation

    Entries that list “PA” in Requirements/Limits imply the payer requires prior authorization documentation to obtain coverage; prescribers must submit the PA request with appropriate supporting information.

    Documentation Required

    Submit PA with quantity and dispensing justification

    When a drug line shows both PA and a QL, prescribers must submit prior authorization including justification for the requested quantity and dispensing interval to meet the QL.

    • Example: submit quantity justification when QL = 60 tablets/30 days is listed.
    Documentation Required

    Provide clinical rationale when submitting PA

    Prescribers must supply the information supporting PA requests for drugs labeled “PA” in the Requirements/Limits field; include clinical rationale and dosing details as needed.

    Prior Authorization

    MOUNJARO — PA required and observe specified QL

    MOUNJARO requires prior authorization and has strength-dependent quantity limits; submit PA and request quantities aligned with the listed QL (4 pens/180 days or 4 pens/28 days as applicable).

    • MOUNJARO — Requirements/Limits = PA, QL (4 pens/180 days or 4 pens/28 days depending on strength)
    Note

    Adhere to listed utilization controls (PA / QL / SP)

    Providers and pharmacies must follow the PA, QL, and SP requirements listed next to each drug; check each product line for the exact utilization controls before dispensing.

    Documentation Required

    Provide documentation for oral solutions and specialty delivery systems

    Documentation to support PA and quantity‑limit requests is expected for oral solutions and specialty items (examples include enalapril oral solution and FUROSCIX); include dosing and volume justification.

    • Enalapril oral solution (Epaned) — Requirements/Limits = PA, QL (1200 mls/30 days)
    • FUROSCIX — Requirements/Limits = PA, QL (8 kits/180 days)
    Documentation Required

    Submit documentation to meet PA and QL requirements

    When PA and QL are listed, providers should submit prior authorization documentation that satisfies the PA criteria and supports the requested quantity within the QL limits.

    Documentation Required

    Ensure PA/QL documentation satisfies payer requirements

    Prescribers must provide required documentation to satisfy PA and QL rules where indicated for individual drugs; failure to provide sufficient evidence may result in denial.

    Billing Rule

    Observe and document quantity limits (QL)

    Observe quantity limits shown in the Requirements/Limits field; QL statements specify maximum supply (e.g., 30 tablets/30 days, 4 pens/28 days) and requests exceeding QL may be denied or require PA justification.

    • Examples: QL (30 tablets/30 days); WEGOVY QL (8 pens/180 days or 4 pens/28 days)
    Documentation Required

    Submit evidence of necessity and dosing with PA requests

    When prior authorization is required, prescribers must supply evidence supporting medical necessity and dosing to meet the listed QL and any SP designation for specialty drugs.

    • Include clinical necessity, prior treatment failures (if applicable), and dose/quantity calculations.
    Denial Risk

    Non‑listed or excluded drugs are not covered — denial risk

    Drugs not included on the BCBSOK Drug List are not covered under the pharmacy benefit; coverage may be denied if the member’s benefit excludes the drug category or the drug is not FDA‑approved.

    Denial Risk

    PA required for select inhaled/antifungal agents — denial risk if not obtained

    Prior authorization is specifically listed for select specialty/inhaled antimicrobials and antifungals (e.g., ARIKAYCE, KITABIS PAK, posaconazole, voriconazole); failure to obtain PA may trigger claim denial.

    • Posaconazole and voriconazole formulations show PA and QL in Requirements/Limits.
    Denial Risk

    PA required for specific HCV agents — risk of denial

    PA is required for certain hepatitis C agents (EPCLUSA, HARVONI, SOVALDI, MAVYRET, VOSEVI); claims submitted without PA may be denied or require retrospective review.

    Documentation Required

    Ensure specialty authorization/handling for SP‑flagged products

    Specialty products flagged “SP” require appropriate specialty authorization and handling; missing specialty authorization or incorrect routing (not using specialty pharmacy) can result in denial.

    • SP flags often accompany PA and QL for biologics and specialty therapies.
    Denial Risk

    PA plus QL entries risk denial if requirements not met

    Drugs listed with both PA and QL indicate coverage may be denied without PA approval or if the requested quantity exceeds the stated QL; obtain PA and request quantities within limits.

    Denial Risk

    Claims may be denied without approved PA

    Claims for drugs labeled “PA” will be subject to prior authorization; lack of an approved PA at time of claim submission may result in claim denial or member financial responsibility.

    Billing Rule

    Route SP drugs through specialty pharmacy and secure PA

    Specialty drugs designated SP typically require specialty pharmacy routing plus PA; failure to follow specialty channel requirements or obtain PA may lead to denial.

    • Examples: XOLAIR, KESIMPTA, AVONEX — Requirements/Limits show PA and SP.
    Denial Risk

    Verify PA and SP for listed products to avoid denial

    When PA or SP is listed for a product (e.g., KALYDECO), coverage may be denied if PA or specialty requirements are not met; verify both PA and SP flags on the product line before prescribing or dispensing.

    • KALYDECO — Requirements/Limits = PA, QL, SP
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Step Edits and Sequences

    Coverage featureDescription / When shownCoverage label
    Step therapy (ST)
    May require trying a proven, cost‑effective medication before coverage of the requested drug. When commonly required it is noted with 'ST' in the Special Requirements column.
    ST indicated where present
    Formulary preferenceExamples from listCoverage label
    Tier preference for strengths/formulations
    Non‑preferred or preferred placement appears by strength/formulation (examples: azithromycin tabs with QL and varying tiers; multiple contraceptive formulations marked AC and tiered).
    ObservationPolicy examplesCoverage label
    No explicit step sequences listed
    Many high‑cost antiviral/HCV agents (e.g., EPCLUSA, HARVONI, MAVYRET) are shown with Prior Authorization (PA) and Quantity Limits (QL) and Specialty (SP) where applicable, but explicit ST sequences are not provided in these excerpts.
    Product typeManagement approachCoverage label
    Specialty oncology drugs
    Managed via Specialty Pharmacy (SP) designation and Prior Authorization (PA); many oncology agents also have Quantity Limits (QL) as listed per product.
    PA / SP where listed
    CategoryNotes / access codesCoverage label
    Contraceptives / access designations
    Some contraceptive entries carry 'AC' (administrative control) and QL (e.g., 28 tablets/21 days); certain formulations may also show PA where required.
    AC or PA as shown
    Drug groupRequirements / limitsCoverage label
    Specialty antidiabetic injectables (GLP‑1/GIP and GLP‑1 agents)
    MOUNJARO, OZEMPIC, TRULICITY and similar agents require Prior Authorization (PA) and have specified Quantity Limits (examples: MOUNJARO QL = 4 pens/28 days or 4 pens/180 days; OZEMPIC QL = 1 pen/28 days or specified ml limits).
    PA required
    FindingSource / implicationCoverage label
    Step therapy not shown in excerpt
    Where step therapy would apply it is indicated in the Requirements/Limits field; this excerpt does not present explicit step sequences for most products.
    ScopeRequirementCoverage label
    Several specialty agents
    Many specialty agents (cardiology/PAH, pulmonary, cystic fibrosis and other specialties) require Prior Authorization (PA); step therapy details are not specified in these entries.
    PA required where listed
    IndicatorExamples / location in listCoverage label
    Step therapy (SP) flagged for specialty agents
    Numerous specialty products are shown with 'SP' and may also have 'ST' noted in Requirements/Limits for step edits; examples and SP flags appear throughout the Requirements/Limits columns for specialty drugs.
    SP / ST where listed
    Example itemRequirements/Limits shownCoverage label
    Risperidone orally disintegrating tablets (ODT)
    Requirements/Limits = QL (60 tablets/30 days), ST for some ODT strengths.
    ST
    Policy noteOperational effectCoverage label
    Entries marked 'ST' require step therapy
    Prescribers must follow the specified step edits (try required alternative therapies first) where 'ST' appears in the Requirements/Limits column; coverage is contingent on meeting the step requirement or obtaining an approved exception/override.
    ST required

    Quantity Limits (QL) by Product

    inv-111: Quantity limits overview — limits may apply and are noted with 'QL' in Requirements/Limits.
    Quantity limits overviewQuantity limits (QL) may apply to listed drugs and are shown as 'QL' in the Requirements/Limits column
    EffectLimits specify maximum quantity in a defined time window (e.g., tablets/30 days, mls/30 days)
    Provider actionWhen QL is present, prescribers must supply documentation to justify quantities exceeding the limit (PA may also be required)
    inv-112: Azithromycin tab 250/500/600 mg — QL 60
    Azithromycin tabsQL 60 (250 mg, 500 mg, 600 mg formulations)
    Where listedShown as QL (60 tablets/180 days) in the macrolides section
    NotesDispensing window may be shown as 180 days for some formulations
    inv-113: ARIKAYCE — amikacin liposome inhal suspension 590 mg/8.4 ml — QL 235.2.
    ARIKAYCE (amikacin liposome inhal suspension 590 mg/8.4 ml)QL 235.2 mls/28 days
    RequirementsEntry notes PA and SP in addition to QL
    Unitmilliliters per 28 days
    inv-114: KITABIS PAK — tobramycin nebu solution 300 mg/5 ml — QL 56.
    KITABIS PAK (tobramycin nebu solution 300 mg/5 ml)QL 56 containers/56 days
    RequirementsListed with PA and SP in the aminoglycosides section
    Interval56-day dispensing window
    inv-115: Itraconazole cap 100 mg — QL 120
    Itraconazole cap 100 mgQL 120 tablets/30 days
    SectionListed under antifungals with QL indicated
    Unittablets per 30 days
    inv-116: Posaconazole / voriconazole formulations — QL 1200.
    Posaconazole / Voriconazole formulationsQL 1200 (ml-equivalent or stated formulation windows)
    RequirementsSome formulations list PA in addition to the QL
    Unitmls/30 days or equivalent per entry
    inv-117: Multiple antiretrovirals (Biktarvy, Truvada, Descovy) — QL 30.
    Multiple antiretrovirals (examples)QL 30 tablets/30 days (Biktarvy, Truvada, Descovy and similar agents)
    ContextCommonly shown with QL 30 in the antivirals/HIV entries
    Provider noteSome entries also include AC/PA flags where applicable
    inv-118: EDURANT PED oral suspension — 1200 mls/30 days
    EDURANT PED (rilpivirine) oral suspension 2.5 mg)QL 1200 mls/30 days
    Where listedShown with QL in the antiviral section
    Unitmilliliters per 30 days
    inv-119: Representative antiviral/antiretroviral examples commonly QL 30 tablets/30 days or other windows (60,90,120,180 days).
    Representative antiviral/antiretroviral examplesCommonly QL 30 tablets/30 days; other windows shown include 60, 90, 120, 180 days depending on product
    ScopeExamples include Truvada, Complera, ISENTRESS, GENVOYA, HARVONI, MAVYRET, SOVALDI, VOSEVI, PAXLOVID
    Where to confirmSee individual drug entries for exact QL and any PA/SP flags
    inv-120: rifaximin (XIFAXAN) 550 mg — QL 60 tablets/30 days
    rifaximin (XIFAXAN) 550 mgQL 60 tablets/30 days
    NotesListed under anti-infectives with QL specified
    Unittablets per 30 days
    inv-121: Multiple specialty/oncology drugs — various QL values as listed (e.g., 120, 240, 90, 60, 30 tablets/30 days).
    Multiple specialty/oncology drugsVarious QL values as listed (examples include 120, 240, 90, 60, 30 tablets/30 days depending on product)
    RequirementMany entries also require PA and are designated SP
    ActionRefer to each product line for the exact QL, PA and SP flags
    inv-122: acalabrutinib 100 mg — QL 60 tablets.
    acalabrutinib 100 mg (CALQUENCE)QL 60 tablets/30 days
    ContextListed with PA and SP in the antineoplastics section
    Unittablets per 30 days
    inv-123: vandetanib 100 mg — QL 60 tablets.
    vandetanib 100 mg (CAPRELSA)QL 60 tablets/30 days
    ContextEntry includes PA and SP
    Unittablets per 30 days
    inv-124: vandetanib 300 mg — QL 30 tablets.
    vandetanib 300 mg (CAPRELSA)QL 30 tablets/30 days
    ContextListed with PA and SP as in the oncology section
    Unittablets per 30 days
    inv-125: cabozantinib kit (COMETRIQ) — QL 1 carton.
    cabozantinib kit (COMETRIQ)QL 1 carton/28 days
    RequirementsEntry lists PA, QL and SP for kit formulations
    IntervalCarton per 28 days
    inv-126: ibrutinib oral suspension 70 mg/ml — QL 216 mls.
    ibrutinib oral suspension 70 mg/mlQL 216 mls/30 days
    ContextListed with PA and SP in oncology agents
    Unitmilliliters per 30 days
    inv-127: imatinib 100 mg — QL 90 tablets.
    imatinib 100 mg (Gleevec)QL 90 tablets/30 days
    RequirementEntry shows PA and SP designation
    Unittablets per 30 days
    inv-128: olaparib 100/150 mg — QL 120 tablets.
    olaparib (LYNPARZA) 100/150 mgQL 120 tablets/30 days
    ContextListed with PA and SP in the antineoplastics section
    Unittablets per 30 days
    inv-129: RETEVMO 40 mg — QL 90 tablets; 80/120/160 mg — QL 60 tablets.
    RETEVMO 40 mgQL 90 tablets/30 days
    RETEVMO 80/120/160 mgQL 60 tablets/30 days
    ContextEntries list PA and SP designations
    inv-131: RUBRACA 200/250/300 mg — QL 120 tablets.
    RUBRACA (rucaparib) 200/250/300 mgQL 120 tablets/30 days
    ContextListed with PA and SP in oncology section
    Unittablets per 30 days
    inv-132: TUKYSA 50 mg — QL 300 tablets.
    TUKYSA (tucatinib) 50 mgQL 300 tablets/30 days
    ContextListed with PA and SP in targeted therapy section
    Unittablets per 30 days
    inv-133: TAGRISSO 40/80 mg — QL 30 tablets.
    TAGRISSO (osimertinib) 40/80 mgQL 30 tablets/30 days
    ContextListed with PA and SP in oncology entries
    Unittablets per 30 days
    inv-134: Testosterone cypionate IM — QL 10 ml.
    Testosterone cypionate IM injQL 10 ml/28 days
    ContextListed under androgen-anabolic products with QL specified
    Unitmilliliters per 28 days
    inv-135: ANNOVERA (vaginal ring) — QL 1 ring.
    ANNOVERA (segesterone acetate-ethinyl estradiol vaginal ring)QL 1 ring (365 days)
    RequirementsListed with AC and QL in contraceptive section
    IntervalOne ring per 365 days
    inv-136: ANNOVERA — QL 1 ring/365 days
    ANNOVERA (yearly)QL 1 ring/365 days
    NotesAppears as AC, QL in the contraceptives section
    Provider noteAdministrative control (AC) may apply as listed
    inv-137: Oral contraceptives (many formulations) — QL 28 tablets/21 days
    Oral contraceptives (many formulations)QL commonly 28 tablets/21 days
    ContextListed with AC and QL flags in the contraceptive section
    IntervalTypically per 21- or 28-day cycle depending on product
    inv-138: ELLA (ulipristal) — QL 2 tablets/365 days
    ELLA (ulipristal acetate)QL 2 tablets/365 days
    RequirementListed with AC and annual QL in contraceptive/EC section
    Unittablets per 365 days
    inv-139: MOUNJARO — QL 4 pens/180 days or 4 pens/28 days (strength-dependent)
    MOUNJARO (tirzepatide)QL 4 pens/180 days or 4 pens/28 days (strength-dependent)
    RequirementEntry indicates PA and QL; strength affects dispensing window
    ActionRefer to specific strength line for exact QL interval
    inv-140: OZEMPIC — QL 1 pen/28 days for lower-dose pens; larger pens QL 3 ml/28 days
    OZEMPIC (semaglutide pen)QL 1 pen/28 days for lower-dose pens; larger-volume pens QL 3 ml/28 days
    RequirementsListed with PA and QL in GLP-1 category
    Unitpen or milliliters per 28 days depending on presentation
    inv-141: RYBELSUS — QL varies by strength (30 tablets/180 days for 3 mg; 30 tablets/30 days for 7 mg and 14 mg)
    RYBELSUS (semaglutide tablets)QL 30 tablets/180 days for 3 mg; 30 tablets/30 days for 7 mg and 14 mg
    RequirementListed with PA and QL in antidiabetic section
    IntervalDifferent QL windows by strength
    inv-142: FIASP, HUMALOG — QL 100 mls/30 days for insulin formulations
    FIASP / HUMALOG (insulin formulations)QL 100 mls/30 days (typical for rapid-acting insulin presentations)
    ContextListed under Rapid-Acting Insulins with QL specified
    Unitmilliliters per 30 days
    inv-143: JANUMET — QL 60 tablets/30 days for some formulations
    JANUMET (some formulations)QL 60 tablets/30 days
    ContextListed with QL in the antidiabetic section
    Unittablets per 30 days
    inv-144: MENOPUR — QL 60 vials
    MENOPUR (menotropins) for injectionQL 60 vials/30 days
    RequirementsListed with QL and SP in fertility medications section
    Unitvials per 30 days
    inv-145: MYCAPSSA — QL 120 capsules
    MYCAPSSA (octreotide delayed-release) 20 mgQL 120 capsules/30 days
    RequirementsEntry notes PA, QL and SP for this specialty product
    Unitcapsules per 30 days
    inv-146: OVIDREL — QL 2 syringes
    OVIDREL (choriogonadotropin alfa) prefilled syringe 250 mcg/0.5 mlQL 2 syringes/30 days
    ContextListed with QL and SP in fertility agents
    Unitsyringes per 30 days
    inv-147: Multiple specialty injectables — QL values as listed (e.g., SOMAVERT 30 vials; VOXZOGO 30 vials; YORVIPATH 2 pens).
    SOMAVERT (pegvisomant)QL 30 vials/30 days
    VOXZOGO (vosoritide)QL 30 vials/30 days
    YORVIPATH (palopegteriparatide)QL 2 pens/28 days
    inv-150: enalapril oral solution (Epaned) — QL 1200 mls
    enalapril oral solution (Epaned)QL 1200 mls/30 days
    RequirementsEntry lists PA and QL in the cardiovascular agents section
    Unitmilliliters per 30 days
    inv-151: FUROSCIX — QL 8 kits
    FUROSCIX - furosemide subcutaneous cartridge kit 80 mg/10 mlQL 8 kits/180 days
    RequirementsEntry requires PA and QL; listed under diuretics/specialty delivery systems
    Interval180-day window
    inv-152: ADEMPAS — QL 90 tablets
    ADEMPAS (riociguat)QL 90 tablets/30 days
    RequirementListed with PA, QL and SP in cardiovascular agents
    Unittablets per 30 days
    inv-153: REPATHA prefilled syringe/pen/cartridge — QL as listed
    REPATHA formulationsQL 6 syringes/28 days; 2 cartridges/30 days; 6 pens/28 days
    RequirementsEntries include PA and SP as applicable
    Unitdevices per specified interval
    inv-154: UPTRAVI — QL 60 tablets
    UPTRAVI (selexipag)QL 60 tablets/30 days
    RequirementsListed with PA and SP in PAH agents
    Unittablets per 30 days
    inv-155: ORENITRAM — QL values as listed
    ORENITRAM (treprostinil diolamine)QL 300 tablets/30 days
    ORENITRAM TITRATION KIT MQL 1 pack/180 days
    RequirementsPA and SP designations noted
    inv-157/158: Pulmonary agent QLs (sildenafil suspension 224 ml; TYVASO refill/starter kit)
    sildenafil citrate for suspension 10 mg/mlQL 224 ml/30 days
    TYVASO refill kitQL 1 pack/28 days (refill); starter kit 1 kit/180 days
    RequirementsPA and SP flags listed for these pulmonary agents
    inv-161: TYVASO/related starter & refill kit QLs
    TYVASO STARTER KITQL 1 kit (starter)
    TYVASO refillQL 1 pack/28 days
    WINREVAIRQL 1 kit/21 days
    inv-167/168/169: Inhaler QL examples
    ASMANEX HFAQL 1 inhaler/30 days or 13 grams/30 days depending on strength
    BREO ELLIPTAQL 1 inhaler/30 days (some strengths 60 blisters/30 days)
    COMBIVENT RESPIMATQL 2 inhalers/30 days
    inv-170/171/173: Examples of inhaled biologic & inhaler QLs
    NUCALA presentationsQL 3 ml/28 days or 1 syringe/28 days depending on presentation
    SPIRIVA HANDIHALER/RESPIMATQL examples: 30 capsules/30 days or 1 cartridge/30 days
    TRELEGY ELLIPTAQL 60 blisters/30 days or 1 inhaler/30 days depending on strength
    inv-175: ALYFTREK, KALYDECO, OFEV, ORKAMBI, PIRFENIDONE, PULMOZYME, SYMDEKO, TRIKAFTA — various QLs
    Cystic fibrosis and related specialty productsVarious QL values listed (examples: KALYDECO 60; ORKAMBI/TRIKAFTA packets 56; PIRFENIDONE 21/180 days)
    RequirementMost such entries include PA and SP as noted
    ActionRefer to each product line for the precise QL interval and units
    inv-176/177/178: Selected CF agent QLs
    KALYDECO (ivacaftor) 150 mgQL 60 tablets/30 days
    PIRFENIDONE (Esbriet) 534 mgQL 21 tablets/180 days (or alternate capsule/tablet windows listed)
    TRIKAFTA granulesQL 56 packets/28 days
    inv-179/180/181: GI and biologic QL examples
    pantoprazole (Protonix) tabletsQL 60 tablets/30 days
    SEVELAMER carbonate packet (Renvela)QL 1530 packets/365 days
    ENTYVIO PEN (vedolizumab)QL 2 pens/28 days
    inv-189: Representative QL examples across the formulary
    Representative QL rangesMany products across therapeutic classes have QLs (examples span 28–365 day windows with counts like 30, 60, 90, 120, 180 days)
    ImplicationProviders must check the specific drug line for exact QL, PA and SP flags before prescribing
    Where to confirmSee the drug list entries and Requirements/Limits column (MyPrime.com / bcbsok.com may provide searchable details)

    Site of Care and Specialty Pharmacy Routing

    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Abbreviations and Key Definitions

    inv-71: Specialty drugs definition — medications used to treat complex conditions and may require specialty handling.
    Specialty drugs definitionMedications used to treat complex conditions that may be oral, topical, or injectable; can be self-administered or administered by a health care professional
    Coverage noteMedications administered by a health care professional may be covered under the medical benefit rather than the pharmacy benefit
    ReferenceVisit MyPrime.com or bcbsok.com for current specialty drug list
    inv-72: Tier definitions — Preferred Generic, Non-Preferred Generic, Preferred Brand, Non-Preferred Brand.
    Tier definitionsPreferred Generic (p), Non-Preferred Generic (np), Preferred Brand (P), Non-Preferred Brand (NP), Preferred Specialty (p/np/P), Non-Preferred Specialty (NP)
    UsageTier letters shown with each product indicate member payment tier and group-specific coverage where '+'' is present
    Where listedTier markers appear next to drug names in the formulary extract
    inv-73: QL / PA / SP definitions — QL = Quantity Limit; PA = Prior Authorization; SP = Specialty.
    QL / PA / SP abbreviationsQL = Quantity Limit; PA = Prior Authorization; SP = Specialty Pharmacy designation
    How shownThese flags appear in the Requirements/Limits column next to each product
    Provider implicationPA typically requires prescriber submission of supporting documentation; SP indicates specialty channel management
    inv-74: PA definition — Prior Authorization explanation.
    PA (Prior Authorization)Prescriber must obtain approval before coverage is provided for drugs listed with 'PA'
    Where appliedPA appears for many high-cost antivirals, specialty and oncology agents in the formulary extract
    Provider actionSubmit clinical documentation consistent with PA requirements when requesting coverage
    inv-75: QL definition — Quantity Limit explanation.
    QL (Quantity Limit)Specifies maximum quantity allowed in a time period (e.g., '60 tablets/30 days', '1200 mls/30 days')
    How enforcedDisplayed as 'QL' in Requirements/Limits; exceeding QL may result in member responsibility or need for PA/exception
    Provider actionIf a greater quantity is needed, prescriber may request PA or an exception per plan process
    inv-76: SP definition — Specialty designation explanation.
    SP (Specialty)Designation indicating product is managed via specialty pharmacy processes and may require specialty handling or distribution
    ImplicationSP items often also have PA and explicit QL; they may require routing to a specialty pharmacy
    Where listedSP flag appears in the Requirements/Limits column for many specialty pulmonary, oncology and biologic agents
    inv-78: Abbreviations used in Requirements/Limits — PA, QL, SP (and AC where shown).
    Abbreviations used in Requirements/LimitsPA = Prior Authorization; QL = Quantity Limit; SP = Specialty Pharmacy; AC = Administrative Control
    Where usedThese abbreviations appear in the Requirements/Limits column and next to contraceptive and specialty entries
    Provider noteRefer to the individual drug entry for the specific combination of flags (e.g., PA, QL, SP, AC)

    Background and Scope

    Specialty drugs are therapies used to manage complex, often chronic or rare conditions (examples cited by the plan include hepatitis, hemophilia, multiple sclerosis, and rheumatoid arthritis). These products may be oral, topical, or injectable and can require special handling, distribution, or clinical oversight. The Drug List is developed by a committee of physicians and pharmacists who consider FDA regulation, safety, efficacy, and cost when selecting products. Many specialty agents are designated SP (managed through specialty pharmacy channels) and may also require prior authorization (PA) and/or specific quantity limits (QL); some medications administered by a health care professional may instead be processed under the medical benefit rather than the pharmacy benefit.